Gilead Sciences Says Magrolimab In Combination With Venetoclax Plus Azacitidine Demonstrated Futility And An Increased Risk Of Death In Patients With AML; Will Not Pursue Further Development Of Magrolimab In Hematologic Cancers
Portfolio Pulse from Benzinga Newsdesk
Gilead Sciences announced that its drug Magrolimab, when combined with Venetoclax and Azacitidine, showed futility and an increased risk of death in AML patients. Consequently, Gilead will halt further development of Magrolimab for hematologic cancers.
February 07, 2024 | 3:16 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Gilead Sciences will cease further development of Magrolimab for hematologic cancers after it failed to show efficacy and increased death risk in AML patients.
The announcement directly impacts Gilead Sciences as it indicates a significant setback in the development of one of its potential treatments. This could negatively affect investor sentiment and potentially the company's future revenue streams from this drug, leading to a likely decrease in stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100